Literature DB >> 30092624

2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.

.   

Abstract

Entities:  

Keywords:  Chronic hepatitis C; Direct acting antivirals; Guidelines; Treatment

Mesh：

Substances：

Year:  2018        PMID： 30092624      PMCID： PMC6166104          DOI： 10.3350/cmh.2018.1004

Source DB:  PubMed          Journal:  Clin Mol Hepatol        ISSN： 2287-2728


× No keyword cloud information.
  202 in total

1.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Authors:  Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns
Journal:  Lancet Infect Dis       Date:  2016-02-18       Impact factor: 25.071

2.  The association between hepatitis C infection and survival after orthotopic liver transplantation.

Authors:  Lisa M Forman; James D Lewis; Jesse A Berlin; Harold I Feldman; Michael R Lucey
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

3.  High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.

Authors:  Stefan Wirth; Carmen Ribes-Koninckx; Maria Angeles Calzado; Flavia Bortolotti; Lucia Zancan; Paloma Jara; Mark Shelton; Nanda Kerkar; Marcela Galoppo; Alejandra Pedreira; Norberto Rodriguez-Baez; Mirta Ciocca; Alain Lachaux; Florence Lacaille; Thomas Lang; Ulrike Kullmer; Wolf Dietrich Huber; Teresita Gonzalez; Henry Pollack; Estella Alonso; Pierre Broue; Jyoti Ramakrishna; Deborah Neigut; Antonio Del Valle-Segarra; Bessie Hunter; Zachery Goodman; Christine R Xu; Hanzhe Zheng; Stephanie Noviello; Vilma Sniukiene; Clifford Brass; Janice K Albrecht
Journal:  J Hepatol       Date:  2010-02-04       Impact factor: 25.083

4.  Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir.

Authors:  Jeffrey M Collins; Kara Loren Raphael; Charles Terry; Emily J Cartwright; Anjana Pillai; Frank A Anania; Monica M Farley
Journal:  Clin Infect Dis       Date:  2015-06-16       Impact factor: 9.079

5.  Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin.

Authors:  A Potthoff; T Berg; H Wedemeyer
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

6.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

7.  High prevalence of HBV and HCV infection among intravenous drug users in Korea.

Authors:  Haesun Yun; Daijin Kim; Soyeon Kim; Sujin Kang; Seunghee Jeong; Yonghoon Cheon; Keunho Joe; Do-Hoon Gwon; Sung-Nam Cho; Youngmee Jee
Journal:  J Med Virol       Date:  2008-09       Impact factor: 2.327

8.  Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.

Authors:  Marc Bourlière; Stuart C Gordon; Steven L Flamm; Curtis L Cooper; Alnoor Ramji; Myron Tong; Natarajan Ravendhran; John M Vierling; Tram T Tran; Stephen Pianko; Meena B Bansal; Victor de Lédinghen; Robert H Hyland; Luisa M Stamm; Hadas Dvory-Sobol; Evguenia Svarovskaia; Jie Zhang; K C Huang; G Mani Subramanian; Diana M Brainard; John G McHutchison; Elizabeth C Verna; Peter Buggisch; Charles S Landis; Ziad H Younes; Michael P Curry; Simone I Strasser; Eugene R Schiff; K Rajender Reddy; Michael P Manns; Kris V Kowdley; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2017-06-01       Impact factor: 91.245

9.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

10.  High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.

Authors:  Fiona McPhee; Yoshiyuki Suzuki; Joji Toyota; Yoshiyasu Karino; Kasuaki Chayama; Yoshiiku Kawakami; Min Lung Yu; Sang Hoon Ahn; Hiroki Ishikawa; Rafia Bhore; Nannan Zhou; Dennis Hernandez; Patricia Mendez; Hiromitsu Kumada
Journal:  Adv Ther       Date:  2015-07-09       Impact factor: 3.845
View more
  15 in total

1.  A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis.

Authors:  Jae Hyun Yoon; Sun Min Kim; Gaeun Kang; Hee Joon Kim; Chung Hwan Jun; Sung Kyu Choi
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

Review 2.  Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases.

Authors:  Soo-Kyung Park; Chang Hwan Choi; Jaeyoung Chun; Heeyoung Lee; Eun Sun Kim; Jae Jun Park; Chan Hyuk Park; Bo-In Lee; Yunho Jung; Dong-Il Park; Do Young Kim; Hana Park; Yoon Tae Jeen
Journal:  Intest Res       Date:  2020-01-30

3.  Development and Evaluation of an Antiviral Agent Medication Adherence Education Program for Patients with Chronic Hepatitis C.

Authors:  Hoo Jeung Cho; Euna Park
Journal:  Int J Environ Res Public Health       Date:  2020-09-07       Impact factor: 3.390

4.  Survival in untreated hepatocellular carcinoma: A national cohort study.

Authors:  Young Ae Kim; Danbee Kang; Hyeyoung Moon; Donghyun Sinn; Minwoong Kang; Sang Myung Woo; Yoon Jung Chang; Boram Park; Sun-Young Kong; Eliseo Guallar; Soo-Yong Shin; Geunyeon Gwak; Joung Hwan Back; Eun Sook Lee; Juhee Cho
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

5.  Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution.

Authors:  Young Joo Park; Hyun Young Woo; Jeong Heo; Sang Gyu Park; Young Mi Hong; Ki Tae Yoon; Dong Uk Kim; Gwang Ha Kim; Hyung Hoi Kim; Geun Am Song; Mong Cho
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519

6.  Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?

Authors:  Jong Eun Yeon
Journal:  Clin Mol Hepatol       Date:  2018-09-11

Review 7.  Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.

Authors:  Jong Eun Yeon
Journal:  Clin Mol Hepatol       Date:  2018-05-02

8.  Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.

Authors:  Naoki Morishita; Ryotaro Sakamori; Tomomi Yamada; Yugo Kai; Yuki Tahata; Ayako Urabe; Ryoko Yamada; Takahiro Kodama; Hayato Hikita; Yoshinori Doi; Shinji Tamura; Hideki Hagiwara; Yasuharu Imai; Sadaharu Iio; Tomohide Tatsumi; Tetsuo Takehara
Journal:  PLoS One       Date:  2020-06-16       Impact factor: 3.240

9.  Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.

Authors:  Carlo Smirne; Antonio D'Avolio; Mattia Bellan; Alessandro Gualerzi; Maria G Crobu; Mario Pirisi
Journal:  Pharmacol Res Perspect       Date:  2021-08

10.  Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.

Authors:  Eun Sun Jang; Kyung-Ah Kim; Young Seok Kim; In Hee Kim; Byung Seok Lee; Youn Jae Lee; Woo Jin Chung; Sook-Hyang Jeong
Journal:  Korean J Intern Med       Date:  2020-06-17       Impact factor: 3.165
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.